Cite
MLA Citation
John Kuruvilla et al.. “Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.” Lancet oncology, vol. 22, no. 4, 2021, pp. 512–524. http://access.bl.uk/ark:/81055/vdc_100124367228.0x000014